SCHEMBL4920155

SCHEMBL4920155

Cc1cccc(C(=O)NCl)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.69
HDAC6 Q9UBN7 1/20 0.69
SMN1; SMN2 Q16637 2/20 0.65
KCNK3 O14649 4/20 0.62
MEN1 O00255 3/20 0.62
KMT2A Q03164 3/20 0.62
KCNK9 Q9NPC2 3/20 0.62
KCNH2 Q12809 1/20 0.62
RXFP1 Q9HBX9 1/20 0.58
POLB P06746 2/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
TP53 P04637 1/20 0.57
PARP1 P09874 1/20 0.57
MAPT P10636 1/20 0.56
CTDSP1 Q9GZU7 1/20 0.56
NT5E P21589 1/20 0.56
GRM5 P41594 1/20 0.54
TAS1R3 Q7RTX0 1/20 0.54
TAS1R1 Q7RTX1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11875152 0.85 HDAC6 (0.52) HDAC8HDAC6SMN1; SMN2MEN1KMT2A
SCHEMBL24931248 0.83 SMN1; SMN2 (0.89) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL82080 0.82 HDAC8 (0.71) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL5242529 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL30929655 0.82 HDAC6 (1.00) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL31540297 0.82 HDAC8 (0.71) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL315826 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL6459633 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL15109023 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2KCNK3MEN1
SCHEMBL661545 0.80 HDAC8 (0.69) HDAC8HDAC6SMN1; SMN2KCNK3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-06-20 US disclosed
CN-103804490-B Thidiazuron antigen and preparation method thereof and application CHINA AGRICULTURAL UNIVERSITY (CN) 2015-11-04 CN disclosed
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199604-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS MAPT, HTT, PSEN1 HDAC8 3320/4885HDAC6 129/4885SMN1; SMN2 9/4885
US-20080051419-A1 AMINE DERIVATIVES USEFUL AS ANTICANCER AGENTS CCNY, CCND2, CCND1 HDAC8 1951/4885HDAC6 589/4885SMN1; SMN2 1349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.